Sam Brusco, Associate Editor06.06.23
Biocomposites, a Keele, U.K.-based company that provides products to regenerate bone and manage infection in bone and soft tissue, has acquired Artoss GmbH, a manufacturer of innovative bone graft substitutes for orthopedics, spine, foot and ankle, and dentistry.
Artoss offers a range of bone graft substitutes using its proprietary NanoBone technology, which is a combination of nanocrystalline hydroxyapatite and silica gel. NanoBone aims to provide optimal bone formation with easy handling.
NanoBone’s special structure activates the body’s bone-forming forces and, according to Biocomposites, leads to very rapid bone healing. In addition to the company’s lead product NanoBone SBX putty, the company has a range of indication-specific product variants that are all ready to use directly from their applicators.
Artoss is located in Rostock, Germany and will continue to develop and manufacture products, but will be able to serve more surgeons thanks to Biocomposites’ established, global distribution network.
Michael Harris, CEO of Biocomposites, commented to the press, "We are delighted to have completed this acquisition of Artoss. Adding the NanoBone range of products to our portfolio provides us with a new differentiated offering to help surgeons treat their patients and a platform from which to develop new ready-to-use products. Following on from our acquisitions of Subiton and Synimed last year, we have established ourselves as the go-to provider for surgeons requiring bone regeneration and/or managing infection in bone and soft tissue."
Biocomposites also began a multiyear agreement with Zimmer Biomet to exclusively distribute its genex bone graft substitute with new mixing system and delivery options in the U.S. in March 2022.
Artoss offers a range of bone graft substitutes using its proprietary NanoBone technology, which is a combination of nanocrystalline hydroxyapatite and silica gel. NanoBone aims to provide optimal bone formation with easy handling.
NanoBone’s special structure activates the body’s bone-forming forces and, according to Biocomposites, leads to very rapid bone healing. In addition to the company’s lead product NanoBone SBX putty, the company has a range of indication-specific product variants that are all ready to use directly from their applicators.
Artoss is located in Rostock, Germany and will continue to develop and manufacture products, but will be able to serve more surgeons thanks to Biocomposites’ established, global distribution network.
Michael Harris, CEO of Biocomposites, commented to the press, "We are delighted to have completed this acquisition of Artoss. Adding the NanoBone range of products to our portfolio provides us with a new differentiated offering to help surgeons treat their patients and a platform from which to develop new ready-to-use products. Following on from our acquisitions of Subiton and Synimed last year, we have established ourselves as the go-to provider for surgeons requiring bone regeneration and/or managing infection in bone and soft tissue."
Biocomposites also began a multiyear agreement with Zimmer Biomet to exclusively distribute its genex bone graft substitute with new mixing system and delivery options in the U.S. in March 2022.
